 The study is a randomized, double-blind, placebo-controlled crossover study. Participants will receive 2.4 grams of oral NAC or similar-appearing placebo during the first visit, and then will cross over to the alternative treatment NAC or placebo for the second and final visit. We will examine endothelial function before and after treatment on each visit. 